Compounds > xylopine
Page last updated: 2024-11-07

xylopine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

xylopine: RN given refers to (R)-isomer; RN for cpd without isomeric designation not available 3/90; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160503
CHEMBL ID452201
CHEBI ID10083
SCHEMBL ID6686161
MeSH IDM0173415

Synonyms (28)

Synonym
517-71-5
xylopine
C09670
6abeta-noraporphine, 9-methoxy-1,2-(methylenedioxy)-
CHEMBL452201
chebi:10083 ,
(-)-xylopine
AC1L4NQM ,
AC1Q6ZQZ ,
nnz7th999h ,
unii-nnz7th999h
SCHEMBL6686161
Q15427929
10-methoxy-6,7,7a,8-tetrahydro-2h,5h-[1,3]benzodioxolo[6,5,4-de]benzo[g]quinoline
DTXSID70965975
(12r)-16-methoxy-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaene
MS-24226
E88996
CS-0198409
(12r)-16-methoxy-3,5-dioxa-11-azapentacyclo[10.7.1.0?,?.0?,??.0??,??]icosa-1(20),2(6),7,14,16,18-hexaene
HY-N9534
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-10-methoxy-, (r)-
(7ar)-6,7,7a,8-tetrahydro-10-methoxy-5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline
(12r)-16-methoxy-3,5-dioxa-11-azapentacyclo[10.7.1.0{2,6}.0{8,20}.0{14,19}]icosa-1(20),2(6),7,14(19),15,17-hexaene
anolobine, o-methyl-
xylopine, (-)-
6a.beta.-noraporphine, 9-methoxy-1,2-(methylenedioxy)-
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-10-methoxy-, (7ar)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aporphine alkaloidAny benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID335141Cytotoxicity against human LUC1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335153Selectivity index, ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335149Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335142Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335143Cytotoxicity against human Col1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335146Cytotoxicity against mouse P388 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335144Cytotoxicity against human KB cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335140Cytotoxicity against human HT1080 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335148Cytotoxicity against human LNCAP cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335154Selectivity index, ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335139Cytotoxicity against human BCA1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335152Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335147Cytotoxicity against human A431 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335150Cytotoxicity against human U373 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335145Cytotoxicity against vinblastine-resistant human KBV1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335151Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.36 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		2.0610monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.0610aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		1.9810aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		1.9810organofluorine compound;
piperidines;
quinolines;
secondary alcohol
corydine
corydine: structure given in first source; RN given refers to (S)-isomer		1.9810
tetrahydropalmatine
[no description available]		1.9810an (S)-7,8,13,14-tetrahydroprotoberberine;
berberine alkaloid;
organic heterotetracyclic compound		adrenergic agent;
dopaminergic antagonist;
non-narcotic analgesic
magnoflorine
magnoflorine: opium alkaloid having the aporphine configuration; RN given refers to parent cpd(S)-isomer; structure. (S)-magnoflorine : An aporphine alkaloid that is (S)-corytuberine in which the nitrogen has been quaternised by an additional methyl group.		1.9810aporphine alkaloid;
quaternary ammonium ion		plant metabolite
stephanine
stephanine: has high affinity for serotonin receptors; RN given refers to (R)-isomer; a precursor to Aristolochic Acids		6.9710
anonaine
anonaine: smooth muscle relaxant; aporphine alkaloid isolated from roots of Annona cherimolia; structure in first source. (-)-annonaine : An aporphine alkaloid that exhibits anti-cancer, trypanocidal and antiplasmodial activites.		1.9810aporphine alkaloid;
organic heteropentacyclic compound;
oxacycle		antineoplastic agent;
antiplasmodial drug;
trypanocidal drug
asimilobine
asimilobine: from Nelumbro nucifera; RN given refers to (R)-isomer		1.9810aporphine alkaloidmetabolite
corydalmine
corydalmine: antagonizes dopamine receptors; structure given in first source; RN given refers to (S)-isomer		1.9810
norcoralydine
norcoralydine: neuromuscular blocking agent; RN given refers to (S)-isomer; structure		1.9810alkaloid
dicentrine
[no description available]		1.9810
reticuline
reticuline: opium alkaloid; dopamine receptor blocker; RN given refers to (S)-isomer; structure. (S)-reticuline : The (S)-enantiomer of reticuline.		1.9810reticulineEC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor
n-methylactinodaphnine
N-methylactinodaphnine: isolated from Illigera luzonensis; structure given in first source		1.9810aporphine alkaloid
quinine
[no description available]		1.9810cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
ConditionIndicatedRelationship StrengthStudiesTrials
B16 Melanoma
[description not available]		02.1310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0610
Allodynia
[description not available]		02.0610
Ache
[description not available]		02.0610
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.0610
Grippe
[description not available]		02.0610
Influenza, Human
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.		02.0610
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710